. 2017 Mar 10;8(16):27481–27488. doi: 10.18632/oncotarget.16078

Table 4. Effects of rs1053239 and rs2479 variation on changes in blood pressure of participants treated with antihypertensive monotherapy during 5-year follow-up.

Medication	Efficacy trait	Adjusted R^{2 a}	β ^a	P ^a	Adjusted R^{2 b}	β ^b	P ^b
Ang II-targeted agents	ΔSBP (mmHg)	0.731	−6.061	< 0.001	0.198	−8.104	< 0.001
	ΔDBP (mmHg)	0.642	−3.311	0.001	0.190	−5.241	< 0.001
CCB	ΔSBP (mmHg)	0.769	5.962	0.003	0.748	2.608	0.135
	ΔDBP (mmHg)	0.765	1.769	0.098	0.766	1.572	0.089
Diuretics	ΔSBP (mmHg)	0.662	1.117	0.480	0.667	−2.679	0.094
	ΔDBP (mmHg)	0.544	−0.599	0.607	0.556	−2.332	0.048

Data were calculated from multivariate linear regression analysis. ^a Adjusted R², ^a β and ^a P for rs1053239 variation with adjustment for age, sex, smoking, alcohol intake, and baseline levels of waist circumference, blood pressure, blood lipid and fasting plasma glucose. ^b Adjusted R², ^b β and ^b P for rs2479 variation with adjustment for age, sex, and baseline levels of waist circumference, blood pressure, blood lipid and fasting plasma glucose. Statistical significance (P < 0.05) is indicated in italics. Ang II-targeted agents for angiotensin II-targeted agents, including angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists, and CCB for calcium channel blockers.